Cost-Effectiveness Analysis of Triple Therapy with Budesonide/ Glycopyrronium/ Formoterol Fumarate versus Dual Therapy in Patients with Chronic Obstructive Pulmonary Disease in Spain

Cost-effectiveness analysis of triple therapy Budesonide/ Glycopyrronium/ Formoterol fumarate versus dual therapies LAMA/LABA and ICS/LABA in COPD patients from the perspective of the Spanish National Health System.

Authors: Juan Antonio Trigueros, Noé Garin, Adolfo Baloira, Susana Aceituno, Ana Calvo, Miriam Prades, Carolina Touron, Anisia Martínez, Covadonga Torres

Year: 2022

Download PDF

Subscribe to Outcomes´10

Name *

E-mail *

Todos los campos marcados con un * son obligatorios

Responsible for the data: Outcomes'10, s.l.u., Purpose: Sending commercial communications. Legitimation: Art. 6.1 Consent of the interested party. Recipient: No data is transferred unless expressly authorised. You may exercise your rights on data protection (access, rectification, opposition, deletion, automated decisions, limitation of treatment, portability) by email at dpo@outcomes10.com. Data will be retained for the time necessary to fulfill its purpose and derived responsibilities by current regulations and the deadlines in the applicable regulations on archives and documentation. In any case, you can request the protection of the Spanish Data Protection Agency through its website www.aepd.es/. In addition, you can consult more information on the privacy policy

I have read and accepted the privacy policy